Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Inge Vrelust"'
Autor:
Agnes Triffet, Stef Meers, Ann De Becker, Julie Bekaert, Michael Beck, Koen Van Eygen, Koen Theunissen, Dominik Selleslag, Timothy Devos, Dries Deeren, Hélène Vellemans, Fleur Samantha Benghiat, Benjamin Bailly, Inge Vrelust, Violaine Havelange, Dominiek Mazure, Gaëtan Vanstraelen, Mia Janssen, Nikki Granacher, Philippe Lewalle, Alain Gadisseur
Publikováno v:
Annals of hematology, Vol. 100, no. 7, p. 1723-1732 (2021)
Annals of Hematology
Annals of hematology
ANNALS OF HEMATOLOGY
Annals of Hematology
Annals of hematology
ANNALS OF HEMATOLOGY
Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in routine practice over 3 years (2016–2019) in Belgium (NCT03678454). Patients with chronic myeloid leukemia (CML) or Philad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea5ca85b03c3f75f625c2fd547f3ef52
https://hdl.handle.net/2078.1/246292
https://hdl.handle.net/2078.1/246292
Autor:
Koen Van Eygen, Koen Theunissen, Michael Beck, Marie Lejeune, Gianfilippo Nifosi, Ann De Becker, Agnes Triffet, Julie Bekaert, Inge Vrelust, Philippe Lewalle, Timothy Devos, Fleur Samantha Benghiat, Dries Deeren, Gaëtan Vanstraelen, Alain Gadisseur, Violaine Havelange, Nikki Granacher, Marc André, Benjamin Bailly, Stef Meers, Dominik Selleslag
Background Iclusig (ponatinib) is a third-generation tyrosine kinase inhibitor (TKI) indicated for adult patients with chronic, accelerated or blast phase CML resistant or intolerant to nilotinib or dasatinib or with Ph+ ALL resistant or intolerant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16093a82877dad151bbd76cd1027886a
https://doi.org/10.1182/blood-2019-127923
https://doi.org/10.1182/blood-2019-127923
Autor:
Koen Theunissen, Steffen Fieuws, Liesbet Lammertijn, G. Bries, Helena Maes, Vincent Maertens, Pierre Zachee, Mariëlle Beckers, Inge Vrelust, Vibeke Vergote, Kristel Buvé, Kathy Goris, Hélène Schoemans, Beata Hodossy, Christine Schuermans, Fabienne Dobbels, Griet Huysmans, Stefaan Meers, Hilde Demuynck, Sabina De Geest, Johan Maertens
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S354
We performed a cross-sectional study to describe the survivorship profile of a convenience sample of 244 allogeneic hematopoietic cell transplantation (HCT) recipients based on a comprehensive health status model and we compared them to controls from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b740e1d0e335137ee9b591adf5f6133f
https://doi.org/10.1016/j.bbmt.2019.12.181
https://doi.org/10.1016/j.bbmt.2019.12.181
Autor:
Mia Janssen, Pierre Zachee, Alain Kentos, Violaine Havelange, Philippe Lewalle, Agnes Triffet, Marc André, Koen Van Eygen, Rik Schots, Alain Gadisseur, Stef Meers, Marie Lejeune, Koen Theunissen, Dominik Selleslag, Timothy Devos, Carolina Kuipers, Fleur Samantha Benghiat, Inge Vrelust, Gaëtan Vanstraelen
Publikováno v:
Blood. 132:1744-1744
Background Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for adult patients with resistant or intolerant chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome-posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e4cb44671c6a30769cf246e7a77800b
https://doi.org/10.1182/blood-2018-99-114070
https://doi.org/10.1182/blood-2018-99-114070
Autor:
Carlos Graux, Verena Voelter, G. Bries, Philippe Mineur, Fabienne Trullemans, Christophe Ravoet, Lucien Noens, Stef Meers, Yves Beguin, Hélène Potier, Dominik Selleslag, Dries Deeren, Inge Vrelust, Koen Theunissen
Publikováno v:
Acta clinica Belgica
ACTA CLINICA BELGICA
ACTA CLINICA BELGICA
Objectives: We evaluated azacitidine (Vidaza (R)) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose, and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32c3c692e4621616e78c7f400848363c
https://hdl.handle.net/10067/1362830151162165141
https://hdl.handle.net/10067/1362830151162165141
Publikováno v:
European journal of emergency medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96acd9a52d3fd8e36ea1c8f5d9632f22
https://doi.org/10.1097/mej.0b013e32834991a0
https://doi.org/10.1097/mej.0b013e32834991a0
Autor:
Edwin Reyniers, Didier G. Ebo, Erik Fransen, Luc S. De Clerck, Vito Sabato, Els van de Vijver, Peter Valent, Geert Mortier, Chris H. Bridts, Inge Vrelust, Margo M. Hagendorens
Publikováno v:
The journal of allergy and clinical immunology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::998403c81eb1e13ba6950c5ec8ba759b
https://pubmed.ncbi.nlm.nih.gov/25086867
https://pubmed.ncbi.nlm.nih.gov/25086867
Autor:
Inge Vrelust, Marc Van der Planken, Inge Vangenechten, Reinhard Schneppenheim, Alain Gadisseur
Publikováno v:
Thrombosis and Haemostasis. 98:464-466
Identification of a novel candidate splice site mutation (0874+1G>A) in a type 3 von Willebrand disease patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3265a3d279bca74945ccebd2688ed270
https://doi.org/10.1160/th06-08-0433
https://doi.org/10.1160/th06-08-0433
Autor:
A. Gadisseur, Girma Minalu, Hilde Jansens, A. Van de Velde, H. Goossens, Wilfried Schroyens, Inge Vrelust, Zwi N. Berneman, Jeroen Mebis, Geert Molenberghs
Publikováno v:
Infection and drug resistance
J Mebis1,2, H Jansens3, G Minalu4, G Molenberghs4, WA Schroyens1, AP Gadisseur1, A van de Velde1, I Vrelust1, H Goossens3, ZN Berneman11Division of Hematology, Antwerp University Hospital, Edegem, 2Division of Medical Oncology, Jessa Hospital, Hassel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b1f68c9725f9d53cfb90b1fc9dea369
https://lirias.kuleuven.be/handle/123456789/286805
https://lirias.kuleuven.be/handle/123456789/286805
Autor:
Ann Van de Velde, Barbara Stein, David Price, Katrien Vermeulen, Yusuke Oji, Katrien Pieters, Emma Gostick, Griet Nijs, Nathalie Cools, I. Jolanda M. de Vries, Zwi N. Berneman, Haruo Sugiyama, Viggo Van Tendeloo, Kristin Ladell, Inge Vrelust, Herman Goossens, Wilfried Schroyens, Alain Gadisseur, Philippe G. Jorens, Sébastien Anguille, Yoshihiro Oka, Evelien Smits, Ann Van Driessche
Publikováno v:
Proceedings of the National Academy of Sciences USA, 107, 31, pp. 13824-9
Proceedings of the National Academy of Sciences USA, 107, 13824-9
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences USA, 107, 13824-9
Proceedings of the National Academy of Sciences of the United States of America
Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have been performed in end-stage cancer patients with h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d040139cf110b80dfdb355ab9e1628f3
https://hdl.handle.net/2066/88044
https://hdl.handle.net/2066/88044